Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy

U

Universitaire Ziekenhuizen KU Leuven

Status

Completed

Conditions

Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)

Treatments

Other: 18-FDG-PET-CT

Study type

Observational

Funder types

Other

Identifiers

NCT01269970
S24640 (Registry Identifier)
G.0175.03

Details and patient eligibility

About

Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown. Our aim was to assess the value of early metabolic response after one cycle of chemotherapy using 18-FDG-PET-CT to predict pathological response and outcome in cT2-4 N0/+ esophageal cancer treated by neoadjuvant CRT and esophagectomy.

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

locally advanced esophageal cancer (cT2-4 N0/+)

Exclusion criteria

  • PET-CT not performed at UZLeuven
  • Other tumor types
  • Distant metastases (organ)

Trial design

0 participants in 1 patient group

locally advanced esophageal carcinoma (cT2-3N0/+)
Treatment:
Other: 18-FDG-PET-CT

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems